Search Images Maps Play YouTube News Gmail Drive More »
Sign in
Screen reader users: click this link for accessible mode. Accessible mode has the same essential features but works better with your reader.

Patents

  1. Advanced Patent Search
Publication numberUSRE37314 E1
Publication typeGrant
Application numberUS 09/141,731
Publication date7 Aug 2001
Filing date27 Aug 1998
Priority date1 Jul 1991
Fee statusPaid
Also published asCA2072945A1, CA2072945C, DE69231530D1, DE69231530T2, DE122009000017I1, DE122009000017I2, EP0521471A1, EP0521471B1, US5260440
Publication number09141731, 141731, US RE37314 E1, US RE37314E1, US-E1-RE37314, USRE37314 E1, USRE37314E1
InventorsKentaro Hirai, Teruyuki Ishiba, Haruo Koike, Masamichi Watanabe
Original AssigneeShionogi Seiyaku Kabushiki Kaisha
Export CitationBiBTeX, EndNote, RefMan
External Links: USPTO, USPTO Assignment, Espacenet
Pyrimidine derivatives
US RE37314 E1
Abstract
The compounds of the present invention inhibit the HMG-CoA reductase, and subsequently suppress the biosynthesis of cholesterol. And they are useful in the treatment of hypercholesterolemia, hyperlipoproteinemia, and atherosclerosis.
Images(9)
Previous page
Next page
Claims(8)
What is claimed is:
1. A compound represented by the formula (I):
wherein
R1 is (1) lower alkyl which may have 1 to 3 substitutents independently selected from the group consisting of halogen, amino, and cyano, (2) C6 to C12 aromatic group which may have 1 to 3 substituents independently selected from the group consisting of lower alkyl, halogen, amino, and cyano, or (3) C1 to C6 lower alkyl substituted by C6 to C12 aromatic group which may have 1 to 3 substituents independently sel-ected from the group consisting of lower alkyl, halo-gen, amino, and cyano; R2 and R3 each is independently (1) hydrogen, (2) lower alkyl which may have 1 to 3 substituents independently selected from the group consisting of halogen, amino, and cyano, or (3) C6 to C12 aromatic group which may have 1 to 3 substituents independently selected from the group consisting of lower alkyl, halogen, amino, and cyano; R4 is (1) hydro-gen, (2) lower alkyl, or a cation capable of forming a non-toxic pharmaceutically acceptable salt; X is sulfur, oxygen, or sulfonyl, or imino which may be substituted by formyl, acetyl, propionyl, butyryl, isobutyryl, vale-ryl, isovaleryl, amino substituted by sulfonyl or alkyl-sulfonyl, and sulfonyl substituted by alkyl, amino or alkylamino, the dotted line represents the presence or absence of a double bond, or the corresponding ring-closed lactone.
2. The compound claimed in claim 1, wherein X is imino which may be substituted by formyl, acetyl, pro-pionyl, butyryl, isobutyryl, valeryl, isovaleryl, amino substituted by sulfonyl or alkylsulfonyl, or sulfonyl substituted by alkyl, amino or alkylamino.
3. The compound claimed in claim 2, wherein X is imino which may be substituted by formyl, acetyl, pro-pionyl, butyryl, isobutyryl, valeryl, isovaleryl, alkylsul-fonylamino, or alkylsulfonyl.
4. The compound claimed in claim 1 having the (3R, 5S)-dihydroxy configuration.
5. A pharmaceutical composition comprising an ef-fective amount of the compound claimed in claim 1 as an active ingredient, in combination with a pharmaceu-tical excipient.
6. The compound 7-( 4 -( 4 -fluorophenyl)- 6 -isopropyl- 2 -(N-methyl-N-methylsulfonylamino)pyrimidin- 5 -yl)-( 3R,5S)-dihydroxy-(E)- 6 -heptenoic acid in the form of a non-toxic pharmaceutically acceptable salt thereof.
7. The compound of claim 6 in the form of a sodium salt.
8. The compound of claim 6 in the form of a calcium salt.
Description

This application is a reissue of U.S. Pat. No. 5,260,440, issued Nov. 8, 1993.

BACKGROUND OF THE INVENTION

1. Field of the Invention

The present invention relates to 3-hydroxy-3-methyl-glutaryl coenzyme A (HMG-CoA) reductase inhibitor.

2. Prior Art

As the first generation of drugs for the treatment of atherosclerosis by inhibiting the activity of HMG-CoA reductase, there are known Mevinolin (U.S. Pat. No. 4,231,938), pravastatin sodium (U.S. Pat No. 4,346,227), and, simvastatin (U.S. Pat. No. 4,444,784), which are fungal metabolites or of the chemical modifications. Recently, synthetic inhibitors of HMG-CoA reductase such as fluvastatin (F. G. Kathawala et al., 8th Int'l Symp. on Atherosclerosis, Abstract Papers, p. 445, Rome (1988)) and BMY 22089 (GB Pat. No. 2,202,846) are developed as the second generation drugs.

SUMMARY OF THE INVENTION

The compounds of the present invention inhibit the HMG-CoA reductase, which plays a main role in the synthesis of cholesterol, and subsequently they suppress the biosynthesis of cholesterol. Therefore, they are useful in the treatment of hypercholesterolemia, hyperlipoproteinemia, and atherosclerosis.

DETAILED DESCRIPTION

The present invention relates to compounds of the formula (I):

wherein R1 is lower alkyl, aryl or aralkyl, each of which may have one or more substituents: R2 and R3 each is independently hydrogen, lower alkyl, or aryl, and each of said lower alkyl and aryl may have one or more substituents; R4 is hydrogen, lower alkyl, or a cation capable of forming a non-toxic pharmaceutically acceptable salt; X is sulfur, oxygen, or sulfonyl, or imino which may have a stubstituent; the dotted line represents the presence or absence of a double bond, or the corresponding ring-closed lactone. This invention also provides a pharmaceutical composition comprising the same.

In the specification, the term “lower alkyl” refers to a straight, branched, or cyclic C1 to C6 alkyl, including methyl, ethyl, n-propyl, isopropyl, cyclopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, cyclobutyl, n-pentyl, isopentyl, neopentyl, tert-pentyl, cyclopentyl, n-hexyl, and isohexyl and the like. Further, the lower alkyl may be substituted by 1 to 3 substituents independently selected from the group consisting of halogen, amino, and cyano. Halogen means fluorine, chlorine, bromine and iodine.

The term “aryl” refers to C6 to C12 aromatic group including phenyl, tolyl, xylyl, biphenyl, naphthyl, and the like. The aryl may have 1 to 3 substituents independently selected from the group consisting of lower alkyl, halogen, amino, and cyano. Preferred aryl is phenyl substituted by 1 to 3 halogens.

The term “aralkyl” refers to C1 to C6 lower alkyl substituted by C6 to C12 aromatic aryl group defined above. Examples of them are benzyl, phenethyl, phenylpropyl and the like, each of which may have 1 to 3 substituents independently selected from the group consisting of lower alkyl halogen, amino, cyano, and the like.

The term “a cation capable of forming a non-toxic pharmaceutically acceptable salt” refers to alkali metal ion, alkaline earth metal ion, and ammonium ion. Examples of alkali metal are lithium, sodium, potassium, and cesium, and examples of alkaline earth metal are beryllium, magnesium, and calcium. Especially, sodium and calcium are preferred.

Examples of “acyl” are formyl acetyl, propionyl, butyryl, isobutyryl, valeryl, and isovaleryl.

In the term “imino which may have a substituent”, preferred substituents are acyl, optionally substituted amino, and substituted sulfonyl.

The term “substituted amino as substituent” means amino group substituted by sulfonyl and alkylsulfonyl. Examples of them are sulfonyl amino and methanesulfonyl amino.

The term “substituted sulfonyl as substituent” means sulfonyl group substituted by alkyl, amino, or alkylamino. Examples of them are methanesulfonyl, sulfamoyl, methylsulfamoyl, and N-methylsulfamoyl.

The compounds of the present invention can be prepared by the following method.

(1) The carboxylate group of the compound a is converted into the alcohol group by the reduction in an appropriate inactive solvent such as THF, ether, and toluene in the presence of the reductant such as LiAlH and DIBAL-H. The reaction is performed at −70 to 50 C., preferably at near room temperature, for 10 minutes to 10 hours, preferably for 30 minutes to 3 hours. Then the obtained alcohol is subjected to oxidation in an appropriate solvent such as methylene chloride in the presence of the oxidizing agent such as TPAP/4-methylmorpholin-N-oxide or pyridium chlorochromate to give aldehyde compound b. The reaction is performed at 0-60 C., preferably at near room temperature, for 10 minutes to 10 hours, preferably 30 minutes to 3 hours.

wherein R1, R2, and R3 each has the same meaning as defined above, and Alkyl means lower alkyl.

(2) The obtained compound b is subjected to reaction with (3R)-or (3S)-3-(tert-butyldimethylsilyloxy-5-oxo-6-triphenylphosphoranylidene hexanoic acid derivatives in an appropriate solvent such as acetonitrile, diethylether, tetrahydrofuran, and dimethylformamide to give the compound c. The reaction is performed for 1-30 hours, preferably for 10-15 hours under heating.

wherein C* means asymmetric carbon atom, the dotted line means the presence or absence of the double bond, R1, R2, R3, and R4each has the same meaning as defined above.

(3) The compound c is subjected to elimination of the tertbutyldimethylsilyl group in an appropriate organic solvent in the presence of hydrogen halogenide to give the compound d.

Every sort of halogen can be used for hydrogen halogenide. Amongst all, hydrogen fluoride is preferred.

The same organic solvents as used in the step (2) may be employed. Acetonitrile is especially preferred.

The reaction is performed in a range of from 0 to 60 C., preferably at room temperature, for 0.5-10 hours, preferably for 1-2 hours.

wherein C*, the dotted line, R1, R2, R3, and R4 each has the same meaning as defined above.

(4) The compound d is reacted with diethylmethoxyborane and NaBH4 in an alcohol-organic solvent mixture and subjected to column chromatography of silica gel to give the compound (I) (in case R4 is lower alkyl). The reaction is performed at a temperature between −100 to 20 C., preferably between −85 to −70 C. under cooling, for 10 minutes to 5 hours, preferably for 30 minutes to 2 hours.

Here, the alcohol includes methanol, ethanol, propanol, and butanol; and the organic solvent includes the same as in the step (3).

Further, if necessary, the obtained compound may be subjected to saponification with the solution of metalic hydroxide (R4: cation), and after the saponification, the reaction mixture is neutralized with an acid and extracted with an organic solvent (R4: hydrogen). The saponification is performed in a popular solvent such as water, acetonitrile, dioxane, acetone, and the mixture thereof, preferably in the presence of a base, by a conventional method. The reaction is performed at 0 to 50 C., preferably at near room temperature.

As metalic hydroxide which may be used are sodium hydroxide, potassium hydroxide, and their analogue.

Acids which may be used include inorganic acids such as hydrochloric acid, sulfuric acid and the like.

wherein C*, the dotted line, R1, R2, R3, and R4 each has the same meaning as defined above.

Further, if necessary, the obtained compounds (I) are subjected to reflux under heating to give the corresponding lactones.

The compound of the present invention can be administered orally or parenterally. For example, the compound of the present invention may be orally administered in the form of tablets, powders, capsules and granules, aqueous or oily suspension, or liquid form such as syrup or elixir, and parenterally in the form of aqueous or oily suspension.

These preparations can be prepared in a conventional manner by using excipients, binders, lubricants, aqueous or oily solubilizers, emulsifier, suspending agents, and the like. And preservatives and stabilizers can be further used.

The dosages may vary with the administration route, age, weight, condition, and the kind of disease of the patients, but are usually 0.5-200 mg/day, preferably 1-100 mg/day through oral route, and 0.1-100 mg/day, preferably 0.5-50 mg/day through parenteral route. They may be used in a single or divided doses.

The present invention is illustrated by the following examples and reference examples, which are not to be considered as limiting.

The abbreviations used in examples and reference examples have the following meanings.

Me: methyl,

Et: ethyl,

i-Pr: isopropyl

t-Bu: tert-butyl,

Ph: phenyl,

DMF: dimethylformamide,

THF: tetrahydrofuran

DDQ: 2,3-dichloro-5,6-dicyano-1,4-benzoquinone

TPAP: tetrapropylammonium perruthenate

HMPA: hexamethylphosphoramide

DIBAL-H: diisobutylaluminum hydride.

REFERENCE EXAMPLE 1 Ethyl 4-(4-fluorophenyl)-6-isopropyl-2-methylthiopyrimidine-5-carboxylate (III-1) and Ethyl 4-(4-fluorophenyl)-6-isopropyl-2-methylsulfonylpyrimidine-5-carboxylate (III-2)

p-Fluorobenzaldehyde 81.81 g is reacted in the same manner as disclosed in the specification of JP Unexamed. Pat. Publn. No. 61-40272 to give 151.0 g (Yield: 86.7%) of the compound 1. Then the mixture of a solution of 44.68 g of the compound 1 in 65 ml of HMPA and 28.24 g of s-methylisourea hydrogen sulfate is stirred at 100 C. for 22 hours. Then the reaction mixture is extracted with ether, and washed with saturated sodium hydrogencarbonate and water in order. The organic layer is dried, and the solvent is distilled away. The obtained residue is subjected to column chromatography of silica gel to give 26.61 g (yield: 46.8%) of the compound 2.

To a solution of the obtained compound 2 in 400 ml of benzene is added 21.64 g (0.095 mmol) or DDQ, and the mixture is stirred for 30 minutes. Then the mixture is subjected to column chromatography of silica gel to give 24.31 g (Yield: 91.9%) of the compound (III-1).

NMR (CDCl3) δ: 1.10 (t, J=7,3H): 1.31 (d, J=7,6 Hz); 2.61 (s, 3H); 3.18 (hept, J=7,1H); 4.18 (q, J=7,2H); 7.12 (m, 2H), 7.65 (m, 2H).

To a solution of 13.28 g (0.04 mmol) of the compound (III-1) in chloroform is added 17.98 g of m-chloroperbenzoic acid, and the reaction mixture is stirred at room temperature. Then it is washed with sodium sulfate and saturated sodium hydrogencarbonate in order. The solution is dried, and the solvent is distilled away and washed with n-hexane to give 13.93 g (Yield 95.7%) of the compound (III-2).

NMR (CDCl3) δ: 1.16 (t, J=7,3H); 1.37 (d, J=7,6H); 3.26 (hept, J=7,1H); 3.42 (s, 3H), 4.28 (q, 2H); 7.18 (m, 2H); 7.76 (m, 2H).

REFERENCE EXAMPLE 2

Another synthetic method of the compound (III-1)

To a solution of 200 mg (0.594 mmol) of the compound 2 in 5 ml of dichloromethane are added 0.5 g (6.10 equivalent) of potassium carbonic anhydride and 166 mg (1.1 equivalent) of iodine, and the mixture is stirred at room temperature for 2.5 hours. After reaction, to the mixture is added saturated sodium hydrogensulfite and extracted with ether. The organic layer is washed with water and dried. The solvent is distilled away under reduced pressure to give 166 mg (Yield: 83.6%) of the compound (III-1) as resinous substance.

NMR (CDCl3) δ: 1.10 (t, 3H, J=7); 1.31 (d, 6H, J=7); 2.61 (s, 3H) 3.17 (heptet, 1H, J=7); 4.18 (q, 2H, J=7); 7.07-7.17 (m, 2H); 7.61-7.69 (m, 2H)

REFERENCE EXAMPLE 3

Another synthetic method of the compound (III-2)

To a solution of 1.0 g (2.97 mmol) of the compound 2 in 10 ml of acetone is added 1.5 g (9.48 mmol) of potassium permanganate, and the mixture is stirred at room temperature for 15 minutes. Acetic acid 1.0 ml is added thereto, and the mixture is stirred at room temperature for further 30 minutes and water is added thereto. The reaction mixture is extracted with ether, washed with saturated sodium hydrogencarbonate and saturated brine and dried over anhydrous magnesium sulfate. The solvent is distilled away under reduced pressure to give 1.07 g (2.94 mmol) (Yield: 99.1%) of the compound (III-2) as crystals.

REFERENCE EXAMPLE 4 Ethyl 4-(4-fluorophenyl)-6-isopropyl-2-(N-methyl-N-methyl-sulfonylamino)pyrimidine-5-carboxylate (III-3) and Ethyl 4-(4-fluorophenyl)-6-isopropyl-2-(N-methyl-N-dimethylsulfamoylamino)pyrimidine-5-carboxylate (III-4)

To a solution of 52.7 g (144 mmol) of the compound (III-2) in 500 ml of absolute ethanol is added gradually a solution of 71.9 ml of 5N methylamine in ethanol under ice-cooling. The reaction mixture is warmed to room temperature, stirred for 1 hour and evaporated under reduced pressure. To the residue is added water, and the mixture is extracted with ether, dried and evaporated under reduced pressure to give 46.9 g (Yield: 100%) of the compound 3. mp. 85-86 C.

Anal Calcd. (%) for C17H20N3FO2: C,64.34; H,6.35; N,13.24: F,5.99. Found: C,64.42, H,6.46: N,13.30; F,6.14.

To a solution of 370 mg (1.213 mmol) of the compound 3 in 5 ml of DMF is added 60 mg of 60% NaH under ice-cooling, and the reaction mixture is stirred for 30 minutes. Methanesulfonyl chloride 208 mg is added thereto, and the mixture is warmed to room temperature and stirred for 2 hours further. To the mixture is added ice-water, and the mixture is extracted with ether. The organic layer is washed with water and dried. The solvent is evaporated under reduced pressure, and the resulting residue is washed with ether-n-pentane to give 322 mg (Yield: 57.6%) of the compound (III-3).

NMR (CDCl3) δ: 1.10 (t, J=7,3H); 1.32 (d, J=7,6H); 3.24 (hept,J=7,1H); 3.52 (s,3H); 3.60 (s, 3H); 4.19 (q, J=7,2H); 7.14 (m, 2H); 7.68 (m, 2H).

To a solution of 4.13 g (13.0 mmol) of the compound 3 in 40 ml of DMF is added 0.57 g of 60% NaH under ice-cooling, and the mixture is warmed to room temperature and stirred for 1 hours. After cooling again, dimethylsulfamoyl chloride 2.43 g (16.9 mmol) is dropwise added thereto, and the mixture is stirred for 2.5 hours. To the mixture is added icewater, and the mixture is extracted with ether washed with water, dried and evaporated under reduced pressure to distill ether. The resulting residue is washed with ether-hexane to give 4.10 g (Yield: 74.2%) of the compound (III-4). mp. 114-116 C.

Anal Calcd. (%) for C19H25N4SFO4: C,53.76; H,5.94; N,13.20; F,4.48. Found: C,53.74: H,5.96; N,13.19; F,4.78.

REFERENCE EXAMPLE 5 Ethyl 4-(4-fluorophenyl)-6-isopropyl-2-methoxypyrimidine-5-carboxylate (III-5) and Ethyl 4-(4-fluorophenyl)-6-isopropyl-2-(N-methyl-N-methylsulfonylhydrazino)pyrimidine-5-carboxylate (III-6)

To a solution of 1.39 g (3.8 mmol) of the compound (III-2) in 60 ml of absolute methanol is added a solution of 0.41 g (7.6 mmol) of sodium methoxide under ice-cooling. The reaction mixture is warmed to room temperature gradually and stirred for 1 hour. The mixture is neutralized with acetic acid and extracted with ether. The organic layer is washed with sodium bicarbonate and water in order, dried and evaporated under reduced pressure to distill ether. The residue is subjected to column chromatography of silica gel to give 1.17 g (Yield: 96.7%) of the compound (III-5).

NMR (CDCl3) δ: 1.10 (t, 3H, J=7 Hz); 1.32 (d, 6H, J=6.6 Hz); 3.21 (m, 1H); 4.08 (s, 3H); 4.18 (q, 2H, J=7 Hz); 7.07-7.74 (m, 4H).

To a solution of 2.50 g (6.77 mmol) of the compound (III-2) in 50 ml of absolute ethanol is added 0.80 g (16.93 mmol) of methyl hydrazine under ice-cooling. The reaction mixture is warmed to room temperature and stirred for 2 hours and extracted with ether. The organic layer is washed with saturated brine and dried to distill the solvent. To a mixture of 2.37 g of the thus obtained compound and a mixture of anhydrous THF and anhydrous pyridine is added 1.03 g (7.84 mmol) of methanesulfonyl chloride under testing. The reaction mixture is warmed to room temperature and stirred for 1.5 hours. To the mixture are added 3 ml of anhydrous pyridine and 1.53 g (11.65 mmol) of methanesulfonyl chloride, and the mixture is stirred for 2 hours. To the reaction mixture is added ice-water and extracted with ether. The organic layer is washed with water and the resulting oily residue is subjected to column chromatography of silica gel to give 2.75 g (Yield: 94.0%) of the compound (III6).

NMR (CDCl3) δ: 1.08 (t, J=7,3H); 1.29 (d, J=7,6H); 2.96 (s, 3H); 3.24 (hept, J=7,1H); 3.59 (s, 3H); 4.16 (q, J=7,2H); 7.14 (m, 2H), 7.63 (m, 2H).

REFERENCE EXAMPLE 6 Methyl (3R)-3-(tert-butyldimethylsilyloxy)-5-oxo-6-triphenylphosphoranylidene hexanate

(1) (3R)-3-(tert-butyldimethylsilyloxy)glutaric acid-1-((R)-(−)mandelic acid ester*1 65 g (164 mmol) is dissolved into 60 ml of methanol, a solution of sodium methoxide in methanol (28% methanol 310 ml, 1.6 mol) is added dropwise thereto under nitrogen atmosphere at 0 C. for 45 minutes at internal temperature under 7 C. The reaction mixture is stirred at 0 C. for 30 minutes and poured into a mixture of 150 ml of conc.HCl, 300 ml of water, and 500 ml of methylene chloride being stirred under ice-cooling and the organic layer is collected. The aqueous layer is extracted with 200 ml of methylene chloride, and each organic layer is washed with dil.HCl and brine in order. Each organic layer are collected and dried over anhydrous magnesium sulfate and evaporated to distill the solvent to give half ester compound.

*1: This compound can be prepared by the method described at page 10 in the specification of KOKAI 2-250852.

1HNMR(CDCl3) δ: 0.08 (s, 3H); 0.09 (s, 3H); 0.86 (s, 9H); 2.52-2.73 (m, 4H); 3.08 (s, 3H); 4.55 (quint, 1H, J=6Hz).

IR (CHCl3): 2880, 1734, 1712, 1438, 1305, 1096, 836 cm−1.

[α]D=−5.00.4 (C=1.04, 23.5 C., CHCl3).

Rf 0.32 (CHCl3/MeOH=9/1).

(2) To a solution of the thus obtained half ester compound in 10 ml of ether are added dropwise triethylamine and ethyl chlorocarboxylate in order under nitrogen atmosphere at −78 C. The resulting white suspension is stirred at 0 C. for 1 hour and cooled to −78 C. The resulting precipitate is filtered under nitrogen atmosphere and the filtrate is washed with 15 ml of ether. To a suspension of 1.29 g ( 3.6 mmol) of methyl bromide triphenylphosphonium in 5 ml of THF is added dropwise butyllithium (1.6M hexane, 2.25 ml, 3.6 mmol) under nitrogen atmosphere at −78 C. The reaction mixture is stirred at 0 C. for 1 hour and cooled to −78 C. and added dropwise to the solution of thus obtained active ester compound in ether. The reaction mixture is washed with 5 ml of THF and stirred at 0 C. for 1 hour, and 10 ml of 5% sodium hydrogencarbonate is added thereto. The reaction mixture is stirred for 5 minutes and extracted with ethyl acetate and the organic layer is separated and the remaining aqueous layer is extracted with ethyl acetate. Each organic layer is collected and washed with brine, dried over anhydrous magnesium sulfate and concentrated. The obtained residue is subjected to column chromatography of silica gel eluting with ether-ethyl acetate and crystallized from ether-hexane to give objective compound.

1HNMR (CDCl3)δ: 0.04 (s, 3H); 0.06 (s, 3H); 0.83 (s, 9H); 2.4-2.9 (m, 4H); 3.64 (s, 3H); 3.74 (d, 1H); 4.5-4.7 (m, 1H); 7.4-7.8 (m, 15H).

IR (CHCl3): 2380, 1730, 1528, 1437, 1250, 1106, 835 cm −1.

[α]D=−6.2 (C=1.27, 22.0 C., CHCl3).

mp.:77.5-78.5 C., Rf=0.48 (CHCl3/MeOH=9/1).

Anal Calcd. (%) for C31H39O4PS: C, 69.63; H,7.35; P,5.79. Found: C, 69.35; H,7.35; P,6.09.

EXAMPLE 1 Sodium (+)-7-[4-(4-fluorophenyl)-6-isopropyl-2-(N-methyl-N-methylsulfonylaminopyrimidin)-5-yl]-(3R,5S)-dihydroxy-(E)-6-heptenate (I a-1)

(1) To a solution of 322 mg of the compound (III-3) obtained in Reference Example 2 in 7 ml of anhydrous toluene is added dropwise 1.4 ml of DIBAL-H in 1.5M toluene at −74 C., and the reaction mixture is stirred for 1 hour and acetic acid is added thereto. The mixture is extracted with ether, and the organic layer is washed with sodium bicarbonate and water, dried and evaporated under reduced pressure to distil ether. The obtained residue is subjected to column chromatography of silica gel eluting with methylene chloride/ether (20/1) to give 277 mg (Yield: 96.1%) of [4-(4-fluorophenyl)-6-isopropyl-2-(N-methyl-N-methylsulfonylamino)pyrimidin-5-yl]methanol 4.

(2) A suspension of 277 mg of the thus obtained compound 4, 190 mg of 4-methylmorpholin-N-oxide, 6 mg of TPAP, 1.0 g of powder molecular sieve 4A, and 10 ml of methylene chloride is stirred for 2 hours. The insoluble matter is filtered off and the two-thirds of the filtrate is distilled away under reduced pressure. The resulting residue is subjected to column chromatography of silica gel eluting with methylene chloride to give 196 mg (Yield: 71.2%) of 4-(4-fluorophenyl)-6-isopropyl-2-(N-methyl-N-methylsulfonylamino)-5-pyrimidinecarbardehyde as crystals.

(3) A solution of 190 mg of the compound 5, 450 mg of methyl (3R)-3-(tert-butyldimethylsilyloxy)-5-oxo-6-triphenylphosphoranylidene hexanate (Reference Example 6), and 5 ml of acetonitrile is refluxed under heating for 14 hours and evaporated under reduced pressure to distill acetonitrile. The resulting residue is subjected to column chromatography of silica gel eluting with methylene chloride to give 233 mg (Yield: 71.3%) of methyl 7-[4-(4-fluorophenyl)-6-isopropyl-2-(N-methyl-N-methylsulfonylamino)pyrimidin-5-yl]-(3R)-3-(tert-butyldimethylsilyloxy)-5-oxo-(E)-6-heptenate 6 as syrup.

(4) To a solution of 16 g of the compound 6 in 100 ml of acetonitrile is added dropwise a solution of 48% hydrogen flouride in 400 ml of acetonitrile (1:19) under ice-cooling, and the mixture is warmed to room temperature and stirred for 1.5 hours. The reaction mixture is neutralized with sodium bicarbonate and extracted with ether. The organic layer is washed with sodium chloride, dried and evaporated under reduced pressure to distil ether to give 13 g (Yield: 100%) of methyl 7-[4-(4-fluorophenyl)-6-isopropyl-2-(N-methyl-N-methylsulfonylamino)pyrimidin-5-yl]-(3R)-3-hydroxy-5-oxo-(E)-6-heptenate 7 as syrup.

(5) To a solution of 13 g of the compound 7 in 350 ml of anhydrous THF and 90 ml of methanol is added a solution of 29.7 ml of 1M diethylmethoxyborane-THF at −78 C., and the mixture is stirred at the same temperature for 30 minutes. To the mixture is added 1.3 g of NaBH4, and the mixture is stirred for 3 hours. Acetic acid 16 ml is added thereto, and the mixture is adjusted to pH 8 with saturated sodium bicarbonate and extracted with ether. The organic layer is washed with water, dried and evaporated ether under reduced pressure. To the resulting residue is added methanol and the mixture is evaporated under reduced pressure for three times. The resulting residue is subjected to column chromatography of silica gel eluting with methylene chloride/ether (3/1) to give 11.4 g (Yield: 85.2%) of methyl 7-[4-(4-fluorophenyl)-6-iso-propyl-2-methyl-N-methylsulfonylamino)pyrimidin-5-yl]-(3R,5S)-dihydroxy-(E)-6-heptenate as syrup.

NMR (CDCl3) δ: 1.27 (d, J=7,6H); 1.53 (m, 2H); 2.47 (d, J=6,2H); 3.36 (hept, J=2H); 3.52 (s, 3H); 3.57 (s, 3H); 3.73 (s, 3H); 4.20 (m, 1H); 4.43 (m, 1H); 5.45 (dd, J=5,16, 1H); 6.64 (dd, J=2,16, 1H); 7.09 (m, 2H); 7.64 (m, 2H).

(6) To a solution of 11.4 g of the compound (I b-1) in 160 ml of ethanol is added 223 ml of 0.1N sodium hydroxide under ice-cooling. The reaction mixture is warmed to room temperature and stirred for 1 hour. The solvent is distilled away under reduced pressure, and ether is added to the resulting residue and the mixture is stirred to give 11.0 g (Yield: 95.0%) of the objective compound (I a-1) as powdery crystals.

[α]D=+18.90.6 (C=1.012, 25.0 C., H2O).

NMR (CDCl3) δ: 1.24 (d, J=7,6H); 1.48 (m, 1H); 1.65 (m, 1H); 2.27 (dd,J=2,6.2H); 3.41 (hept, J=7,1H); 3.48 (s, 3H); 3.59 (s, 3H); 3.73 (m, 1H); 4.32 (m 1H); 5.49 (dd, J=7,16 1H); 6.62 (d, J=16,1H); 7.19 (m, 2H); 7.56 (m, 2H).

EXAMPLE 2 Sodium (+)-7-[4-(4-fluorophenyl)-6-isopropyl-2-(N-acetyl-N-methylamino)pyrimidin-5-yl]-(3R,5S)-dihydroxy-(E)-6-heptenate (I a-2)

(1) Ethyl 4-(4-fluorophenyl-6-isopropyl-2-methylaminopyrimidine-5-carboxylate 3 838 mg obtained in Reference Example 4 is allowed to react in the same manner as in Example 1 (1) and (2) to give 157 mg of 4-(4-fluorophenyl)-6-isopropyl-2-methylaminopyrimidine-5-carbaldehyde.

(2) A solution of 157 mg of thus obtained aldehyde compound in 4 ml of anhydrous DMF is reacted with 25 mg of 60% NaH under ice-cooling for 30 minutes, 0.05 ml of acetylchloride is added thereto and the mixture is stirred for 1 hour. The mixture is added with ice and extracted with ether. The organic layer is washed with water and dried and concentrated to distill the solvent to give 167 mg (Yield: 93.4%) of 4-(4-fluorophenyl)-6-isopropyl-2-(N-acetyl-N-methylamino)pyrimidine-5-carbardehyde. Thus obtained aldehyde compound is reacted in the same manner as in Example 1 (3)-(5) to give methyl 7-[4-(4-fluorophenyl)-6-isopropyl-2-(N-acetyl-N-methylaminopyrimidin)-5-yl]-(3R,5S)-dihydroxy-(E)-6-heptenate (I b-2).

NMR (CDCl3)δ: 1.27 (d, J=7,6H); 1.54 (m, 2H); 2.48 (d, J=6,2H); 2.52 (s, 3H); 3.39 (hept, J=7, 1H); 3.60 (s, 3H); 3.58 (brs, 1H); 3.74 (s, 3H): 4.21 (m, 1H); 4.48 (m, 1H); 5.50 (dd, J=5,16, 1H); 6.66 (dd, J=2,16); 7.11 (m, 2H); 7.61 (m, 2H).

(3) The thus obtained compound (I b-2) is reacted in the same manner as Example 1 (6) to give the objective compound (I a-2).

NMR (CDCl3)δ: 1.27 (d, J=7,6H); 1.57 (m, 2H): 2.17 (s, 3H); 2.27 (d, J=6,2H); 3.72 (s, 3H); 3.50 (hept, J=7, 1H); 3.70 (m, 1H); 4.35 (q, J=6,1H); 5.59 (dd, J=5,16, 1H); 6.54 (d, J=16, 1H); 7.24 (m, 2H): 7.59 (m, 2H).

EXAMPLE 3-6

As a starting material, each pyrimidine carboxylate (III) obtained in Reference Example 1-3 is reacted in the same manner as Example 1 or 2 to give the compound (I b) and (I a). Their physical constants are shown in Table 1-3.

TABLE 1
Ex. Startup Product
No. material NMR δ
3 (Ill-1) 1b-3(X: S)Yield 96.0% (CDCl3,
1.26(d, J = 7.6H): 1.52(m, 2H): 2.47(d, J = 6,
2H): 2.60(s, 3H): 3.33(hept, J = 7, 1H): 3.73
(s, 3H): 4.18(m, 1H): 4.44(m, 1H): 5.44(dd,
J = 5, 16, 1H): 6.60(dd, J = 2, 16, 1H), 7.07(m,
2H): 7.58(m, 2H)
1a-3(X: S)Yield 87.3% (D2O)
1.20(d, J = 7, 6H): 1.47(m, 1H): 1.61(m, 1H):
2.26(m, 2H), 2.54(s, 3H): 3.36(hept, J = 7, 1H):
3.71(m, 1H): 4.29(m, 1H): 5.43(dd, J = 6, 16,
1H): 6.55(d, J = 16, 1H): 7.16(m, 2H), 7.47
(m, 2H)
4 (Ill-2) 1b-4(X: SO2): Yield 93.7% (CDCl3)
1.31(d, J = 7, 6H): 1.52(m, 2H): 2.48(d, J = 6,
2H): 3.40(s, 3H); 3.47(hept, J = 7, 1H); 3.74
(s, 3H): 3.87(brs, 1H): 4.23(m, 1H): 4.49
(m, 1H); 5.59(dd, J = 5, 16H, 1H); 6.74(d, d, J =
2, 16, 1H); 7.12(m, 2H): 7.69(m, 2H)
1a-4(X: SO2): Yield 70.9% (D2O)
1.27(d, d, J = 7, 2, 6H); 1.60(m, 2H); 2.25(J =
6, d, 2H): 3.44(s, 3H): 3.51(hept, J = 7, 1H):
3.70(m, 1H): 4.33(q, J = 6, 1H): 5.65(d, d, J = 5,
16, 1H): 6.71(d, J = 16, 1H): 7.23(m, 2H); 7.60
7.60(m, 2H)

TABLE 1
Ex. Startup Product
No. material NMR δ
3 (Ill-1) 1b-3(X: S)Yield 96.0% (CDCl3,
1.26(d, J = 7.6H): 1.52(m, 2H): 2.47(d, J = 6,
2H): 2.60(s, 3H): 3.33(hept, J = 7, 1H): 3.73
(s, 3H): 4.18(m, 1H): 4.44(m, 1H): 5.44(dd,
J = 5, 16, 1H): 6.60(dd, J = 2, 16, 1H), 7.07(m,
2H): 7.58(m, 2H)
1a-3(X: S)Yield 87.3% (D2O)
1.20(d, J = 7, 6H): 1.47(m, 1H): 1.61(m, 1H):
2.26(m, 2H), 2.54(s, 3H): 3.36(hept, J = 7, 1H):
3.71(m, 1H): 4.29(m, 1H): 5.43(dd, J = 6, 16,
1H): 6.55(d, J = 16, 1H): 7.16(m, 2H), 7.47
(m, 2H)
4 (Ill-2) 1b-4(X: SO2): Yield 93.7% (CDCl3)
1.31(d, J = 7, 6H): 1.52(m, 2H): 2.48(d, J = 6,
2H): 3.40(s, 3H); 3.47(hept, J = 7, 1H); 3.74
(s, 3H): 3.87(brs, 1H): 4.23(m, 1H): 4.49
(m, 1H); 5.59(dd, J = 5, 16H, 1H); 6.74(d, d, J =
2, 16, 1H); 7.12(m, 2H): 7.69(m, 2H)
1a-4(X: SO2): Yield 70.9% (D2O)
1.27(d, d, J = 7, 2, 6H); 1.60(m, 2H); 2.25(J =
6, d, 2H): 3.44(s, 3H): 3.51(hept, J = 7, 1H):
3.70(m, 1H): 4.33(q, J = 6, 1H): 5.65(d, d, J = 5,
16, 1H): 6.71(d, J = 16, 1H): 7.23(m, 2H); 7.60
7.60(m, 2H)

TABLE 3
Ex. Starting Product
No. material NMR δ
7 (Ill-6) 1b-7(X: N—NHSO2Me): Yield: 87.8% (CDCl3)
1.24(d, J = 7, 6H): 1.51(m, 2H): 2.47(d, J = 6,
2H); 2.95(s, 3H); 3.35(hept, J = 7, 1H); 3.46
(d, J = 2, 1H): 3.55(s, 3H); 3.66(d, J = 2, 1H): 3.74
(s, 3H): 4.18(m, 1H): 4.44(m, 1H): 5.41
(dd, J = 5, 16, 1H); 6.58(dd, J = 2, 16, 1H); 7.09(m,
2H); 7.58(m, 2H), 7.70(s, 1H)
1a-7(X: N—NHSO2Me): Yield: 74.7% (D2O)
1.23(d, J = 7, 6H): 1.51(m, 2H): 2.26(d, J = 6, 2H)
3.10(s, 3H); 3.37(hept, J = 7, 1H): 3.44
(s, 3H): 3.70(m, 1H). 4.29(q, J = 6, 1H): 5.39
(dd, J = 5, 16, 1H): 6.58(d, J = 16, 1H): 7.19(m,
2H):7.52(m, 2H)

EXAMPLE 7

Calcium salt of the compound (I a-1) (sodium salt) 1.50 g (3.00 mmol) is dissolved in 15 ml of water and stirred at room temperature under nitrogen atmosphere, successively 3.00 ml (3.00 mmol) of 1 mol/L calcium chloride 3.00 ml (3.00 mmol) is added dropwise thereto over 3 minutes. The reaction mixture is stirred at the same temperature for 2 hours, and the resulting precipitate is collected, washed with water and dried to give 1.32 g of calcium salt as powdery. This compound started to melt at a temperature of 155 C., but the definitive melting point is ambiguous.

[α]D=+6.3 0.2 (C=2.011, 25.0 C., MeOH).

Anal Calcd. (%) for C22H27N3O6SF . 0.5Ca . 0.5H2O: C,51.85; H,5.53; N,8.25; F,3.73; Ca,3.93. Found: C,51.65; H,5.51; N,8.47; F,3.74; Ca,4.07.

Biological Activity Experiment The HMG-CoA reductase inhibitory effect

(1) Preparation of rat liver microsome

Sprague-Dawley rats, which were in free access to ordinary dietes containing 2% cholestyramine and water for 2 weeks, were used for the preparation of rat liver microsome. The thus obtained microsome was the purified according to the manner by Juroda et al., Biochem. Biophys. Act, 486, 70 (1977). The microsomal fraction obtained by centrifugation at 105,000g was washed once with a buffered solution containing 15 mM nicotinamide and 2 mM magnesium chloride (in a 100 mM potassium phosphate buffer, pH 7.4). It was homogenized with a buffer containing nicotinamide and magnesium chloride at the same weight as the liver employed. The thus obtained homogenate was cooled down and kept at −80 C.

(2) Measurement of the HMG-CoA reductase inhibitory activities

The rat liver microsome sample (100 μl), which was preserved at −80 C., was fused at 0 C. and diluted with 0.7 ml of a cold potassium phosphate buffer (100 mM, pH7.4). This was mixed with 0.8 ml of 50 mM EDTA (buffered with the aforementioned potassium phosphate buffer) and 0.4 ml of 100 mM dithiothreitol solution (buffered with the aforementioned potassium phosphate buffer), and the mixture was kept at 0 C. The microsome solution (1.675 ml) was mixed with 670 μl of 25 mM NADPH (buffered with the aformentioned potassium phosphate buffer), and the solution was added to the solution of 0.5 mM [3−14](HMG-CoA (3mCi/mmol). A solution (5 μl) of sodium salt of the test compound dissolved in potassium phosphate buffer is added to 45 μl of the mixture. The resulting mixture was incubated at 37 C. for 30 minutes and cooled. After termination of the reaction by addition of 10 μl of 2NHCl, the mixture was incubated again at 37 C. for 15 minutes and then 30 μl of this mixture was applied to thin-layer chromatography of silica gel of 0.5 mm in thickness (Merck AG, Art 5744). The chromatograms were developed in toluene/acetone (1/1) and the spot, whose Rf value was between 0.45 to 0.60, were scraped. The obtained products were put into a vial containing 10 ml of scintillator to measure specific radio-activity with scintillation counter. The activities of the present compounds are shown in Table 4 as comparative ones based on the assumption that the activity of Mevinolin (sodium salt) as reference drug is 100.

TABLE 4
Test Compound HMG-CoA reductase inhibitory activities
1a-1 442
1a-3 385
1a-5 279
1a-7 260
Mevinolin Na 100

From the test data, the compounds of the present invention exhibit HMG-CoA reductase inhibition activities superior to Mevinolin.

Patent Citations
Cited PatentFiling datePublication dateApplicantTitle
US486818510 Dec 198719 Sep 1989Warner-Lambert Company6-[[Substituted)pyrimidinyl)ethyl]- and ethenyl]tetrahydro-4-hydroxypyran-2-one inhibitors of cholesterol biosynthesis
US49258528 Jul 198815 May 1990Hoechst Aktiengesellschaft3-demethylmevalonic acid derivatives, and pharmaceutical products based on these compounds
US502670812 Sep 198825 Jun 1991Nissan Chemical Industries Ltd.Pyrimidine type mevalonolactones
EP0330057A215 Feb 198930 Aug 1989Bayer AgSubstituted pyrimidines
EP0367895A16 Mar 198916 May 1990Sandoz AgPyrimidinyl-substituted hydroxyacids, lactones and esters and pharmaceutical compositions containing them
Non-Patent Citations
Reference
1B. Roth et al., J. Med. Chem., 34, 463-466 (1991).
2G. Beck et al., J. Med. Chem., 33, 52-60 (1990).
3Moore et al, J. Am. Chem. Soc., vol. 107, pp. 3694-3701, 1985.*
Referenced by
Citing PatentFiling datePublication dateApplicantTitle
US677755216 Aug 200217 Aug 2004Teva Pharmaceutical Industries, Ltd.Processes for preparing calcium salt forms of statins
US72448442 Dec 200417 Jul 2007Teva Pharmaceutical Industries Ltd.Reference standard for characterization of rosuvastatin
US737175921 Sep 200413 May 2008Bristol-Myers Squibb CompanyHMG-CoA reductase inhibitors and method
US739692724 Aug 20048 Jul 2008Teva Pharmaceutical Industries Ltd.Process for preparation of rosuvastatin calcium
US758275912 Sep 20061 Sep 2009Teva Pharmaceutical Industries Ltd.Diastereomeric purification of rosuvastatin
US761220322 Feb 20063 Nov 2009Teva Pharmaceutical Industries Ltd.Rosuvastatin and salts thereof free of rosuvastatin alkylether and a process for the preparation thereof
US76557967 Feb 20072 Feb 2010Teva Pharmaceutical Industries Ltd.Process for the preparation of rosuvstatin
US768766018 Apr 200830 Mar 2010Teva Pharmaceutical Industries Ltd.Process for preparing intermediates of HMG-CoA reductase inhibitors
US769200825 Jun 20076 Apr 2010Teva Pharmaceutical Industries Ltd.Reference standard for characterization of rosuvastatin
US769200925 Jun 20076 Apr 2010Teva Pharmaceutical Industries Ltd.Reference standard for characterization of rosuvastatin
US769201025 Jun 20076 Apr 2010Teva Pharmaceutical Industries Ltd.Reference standard for characterization of rosuvastatin
US774148225 Jun 200722 Jun 2010Teva Pharmaceutical Industries Ltd.Reference standard for characterization of rosuvastatin
US777703424 Nov 200417 Aug 2010Teva Pharmaceutical Industries Ltd.Crystalline ammonium salts of rosuvastatin
US785162413 Mar 200814 Dec 2010Teva Pharamaceutical Industries Ltd.Triol form of rosuvastatin and synthesis of rosuvastatin
US786816916 Aug 200611 Jan 2011Teva Pharmaceutical Industries, Ltd.Crystalline rosuvastatin intermediate
US788422614 Jul 20088 Feb 2011Teva Pharmaceutical Industries, Ltd.Purification of rosuvatatin intermediate by thin film evaporation and chemical method
US79647484 Feb 201021 Jun 2011Teva Pharmaceutical Industries, Ltd.Process for preparing intermediates of HMG-CoA reductase inhibitors
US806321111 Mar 200922 Nov 2011Teva Pharmaceutical Industries, Ltd.Rosuvastatin and salts thereof free of rosuvastatin alkylether and a process for the preparation thereof
US81583629 Nov 200517 Apr 2012Decode Genetics Ehf.Methods of diagnosing susceptibility to myocardial infarction and screening for an LTA4H haplotype
US821203411 Dec 20073 Jul 2012Aurobindo Pharma Ltd.Process for preparing rosuvastatin calcium
US82120354 Feb 20083 Jul 2012Aurobindo Pharma Ltd.Process for preparation of rosuvastatin calcium field of the invention
US831893329 Oct 200727 Nov 2012Aurobindo Pharma LtdProcess for preparing rosuvastatin calcium
US847643230 Jun 20112 Jul 2013Yuhan CorporationProcess for the preparation of HMG-COA reductase inhibitors and intermediates thereof
US848709727 Jan 200916 Jul 2013Teva Pharmacedutical Industries Ltd.Reference standard for characterization of rosuvastatin
US85249148 Apr 20103 Sep 2013Chong Kun Dang Pharmaceutical Corp.Method for preparing rosuvastatin, intermediate compounds useful for preparing same, and method for preparing same
US867388113 Apr 201018 Mar 2014A.T. Resolve SarlCompositions and methods for the treatment of inflammation
US8729092 *24 Sep 201220 May 2014Terence J. ScallenRosuvastatin enantiomer compounds
US884691517 Aug 200930 Sep 2014Aurobindo Pharma Ltd.Process for the manufacture of rosuvastatin calcium using crystalline rosuvastatin ethyl ester
US929670218 Apr 201429 Mar 2016Terence J. ScallenRosuvastatin enantiomer compounds
US931544712 Mar 201419 Apr 2016A.T. Resolve SarlCompositions and methods for the treatment of inflammation
US951802818 Nov 201313 Dec 2016Suven Life Sciences LimitedProcess for the preparation of Rosuvastatin calcium and preparation of its novel intermediates
US20030181500 *26 Feb 200325 Sep 2003Sankyo Company, LimitedMedicinal compositions for the prevention or treatment of cardiac failure
US20040132771 *6 Oct 20038 Jul 2004Pfizer IncCompositions of choleseteryl ester transfer protein inhibitors and HMG-CoA reductase inhibitors
US20040176615 *18 Mar 20049 Sep 2004Valerie Niddam-HildesheimProcesses for preparing calcium salt forms of statins
US20050085497 *21 Sep 200421 Apr 2005Saleem AhmadHMG-CoA reductase inhibitors and method
US20050131066 *24 Nov 200416 Jun 2005Valerie Niddam-HildesheimCrystalline ammonium salts of rosuvastatin
US20050187234 *2 Dec 200425 Aug 2005Nina FinkelsteinReference standard for characterization of rosuvastatin
US20050197501 *2 May 20058 Sep 2005Teva Pharmaceutical Industries Ltd.Processes for preparing calcium salt forms of statins
US20060019269 *30 Mar 200526 Jan 2006Decode Genetics, Inc.Susceptibility gene for myocardial infarction, stroke, and PAOD, methods of treatment
US20070037979 *22 Feb 200615 Feb 2007Valerie Niddam-HildesheimPreparation of rosuvastatin
US20070048351 *18 Aug 20061 Mar 2007Prescient Medical, Inc.Drugs coated on a device to treat vulnerable plaque
US20070099994 *16 Aug 20063 May 2007Valerie Niddam-HildesheimRosuvastatin calcium with a low salt content
US20070123550 *16 Aug 200631 May 2007Valerie Niddam-HildesheimCrystalline rosuvastatin intermediate
US20070142418 *7 Feb 200721 Jun 2007Teva Pharmaceuticals Usa, Inc.Process for the preparation of rosuvastatin
US20070167625 *4 Oct 200619 Jul 2007Anna BalanovPreparation of rosuvastatin
US20070179166 *12 Sep 20062 Aug 2007Valerie Niddam-HildesheimProcess for preparation of statins with high syn to anti ratio
US20070191436 *12 Sep 200616 Aug 2007Valerie Niddam-HildesheimDiastereomeric purification of rosuvastatin
US20070244321 *25 Jun 200718 Oct 2007Teva Pharmaceuticals Usa, Inc.Reference standard for characterization of rosuvastatin
US20070249830 *25 Jun 200725 Oct 2007Teva Pharmaceutical Industries Ltd.Reference standard for characterization of rosuvastatin
US20070249831 *25 Jun 200725 Oct 2007Teva Pharmaceutical Industries Ltd.Reference for characterization of rosuvastatin
US20070254897 *27 Apr 20071 Nov 2007Resolvyx Pharmaceuticals, Inc.Compositions and methods for the treatment of cardiovascular disease
US20070255059 *25 Jun 20071 Nov 2007Teva Pharmaceuticals Usa, Inc.Reference standard for characterization of rosuvastatin
US20080206328 *2 Feb 200528 Aug 2008Ferrer International, S.A.Hypocholesterolemic Compositions Comprising a Statin and an Antiflatulent Agent
US20080234302 *20 Sep 200525 Sep 2008Mohammad RafeeqNovel Processes for Preparing Amorphous Rosuvastatin Calcium and a Novel Polymorphic Form of Rosuvastatin Sodium
US20080248115 *7 Apr 20089 Oct 2008Palepu Nageswara RCombinations of statins and anti-obesity agent
US20080249141 *7 Apr 20089 Oct 2008Palepu Nageswara RCo-therapy with and combinations of statins and 1,4-dihydropyridine-3,5-dicarboxydiesters
US20080249156 *7 Apr 20089 Oct 2008Palepu Nageswara RCombinations of statins and anti-obesity agent and glitazones
US20080269270 *13 Mar 200830 Oct 2008Valerie Niddam-HildesheimTriol form of rosuvastatin and synthesis of rosuvastatin
US20080293750 *31 Jan 200527 Nov 2008Anna HelgadottirSusceptibility Gene for Myocardial Infarction, Stroke, Paod and Methods of Treatment
US20090036680 *19 Jan 20055 Feb 2009Ranbaxy Laboratories LimitedSalts of hmg-coa reductase inhibitors and use thereof
US20090069563 *14 Jul 200812 Mar 2009Valerie Niddam-HildesheimRosuvastatin intermediates and their preparation
US20090076271 *18 Apr 200819 Mar 2009Vinod Kumar KansalProcess for preparing intermediates of HMG-CoA reductase inhibitors
US20090076292 *18 Apr 200819 Mar 2009Teva Pharmaceutical Industries Ltd.Rosuvastatin intermediates and process for the preparation of rosuvastatin
US20090099383 *14 Jul 200816 Apr 2009Tamar NidamPurification of rosuvatatin intermediate by thin film evaporation and chemical method
US20090187026 *26 Feb 200923 Jul 2009Teva Pharmaceuticals Usa, Inc.Diastereomeric purification of rosuvastatin
US20090209779 *21 Apr 200920 Aug 2009Teva Pharmaceutical Industries Ltd.Process for preparing intermediates of HMG-CoA reductase inhibitors
US20090215806 *4 May 200927 Aug 2009Valerie Niddam-HildesheimRosuvastatin calcium with a low salt content
US20090240054 *4 May 200924 Sep 2009Teva Pharmaceuticals Usa, Inc.Rosuvastatin calcium with a low salt content
US20090312547 *4 Feb 200817 Dec 2009Ramesh DandalaProcess for preparation of rosuvastatin calcium field of the invention
US20100029940 *11 Dec 20074 Feb 2010Ramesh DandalaProcess for preparing rosuvastatin calcium
US20100048899 *29 Oct 200725 Feb 2010Ramesh DandalaProcess for preparing rosuvastatin calcium
US20100069635 *29 Nov 200718 Mar 2010Dr. Reddy's Laboratories Ltd.Rosuvastatin dehydroabietylamine salt
US20100160663 *4 Feb 201024 Jun 2010Teva Pharmaceutical Industries Ltd.PROCESS FOR PREPARING INTERMEDIATES OF HMG-CoA REDUCTASE INHIBITORS
US20100197916 *2 Feb 20105 Aug 2010Teva Pharmaceutical Industries Ltd.Diastereomeric purification of rosuvastatin
US20100216863 *30 Mar 200626 Aug 2010Decode Genetics Ehf.Susceptibility Gene for Myocardial Infarction, Stroke, and PAOD; Methods of Treatment
US20100234443 *21 May 201016 Sep 2010Scidose LlcCombinations of statins and anti-obesity agent
US20110178296 *23 Sep 200921 Jul 2011Sambhu Prasad Sarma MallelaProcess for preparing pyrimidine propenaldehyde
EP1961419A19 Dec 200327 Aug 2008Pfizer Products Inc.Dosage forms comprising a CETP inhibitor and an HMG-CoA reductase inhibitor
EP2392567A119 Oct 20067 Dec 2011Bristol-Myers Squibb CompanyBenzothiazine derivatives and their use as lxr modulators
EP2428516A119 Nov 200414 Mar 2012Metabasis Therapeutics, Inc.Novel phosphorus-containing thyromimetics
WO2006091770A3 *22 Feb 200631 May 2007Teva PharmaRosuvastatin and salts thereof free of rosuvastatin alkylether and a process for the preparation thereof
WO2006091771A3 *22 Feb 200611 Jan 2007Anna BalanovPreparation of rosuvastatin
WO2007040940A1 *12 Sep 200612 Apr 2007Teva Pharmaceutical Industries Ltd.Diastereomeric purification of rosuvastatin
WO2007050425A219 Oct 20063 May 2007Bristol-Myers Squibb CompanyLxr modulators
WO2007062314A216 Nov 200631 May 2007Bristol-Myers Squibb CompanyHeterocyclic cetp inhibitors
WO2010093601A19 Feb 201019 Aug 2010Metabasis Therapeutics, Inc.Novel sulfonic acid-containing thyromimetics, and methods for their use
WO2011018185A229 Jul 201017 Feb 2011Synthon B.V.Pharmaceutical tablet comprising rosuvastatin calcium
WO2011019326A225 Jun 201017 Feb 2011Mahmut BilgicSolubility and stability enchancing pharmaceutical formulation
WO2011141934A112 May 201117 Nov 2011Matrix Laboratories Ltd.An improved process for the preparation of an intermediate of hmg-coa reductase inhibitors
WO2012027331A123 Aug 20111 Mar 2012Ironwood Pharmaceuticals, Inc.Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders
WO2012063115A29 Nov 201118 May 2012Jubilant Life Sciences Ltd.Process for the preparation of rosuvastatin calcium via novel amine intermediate
WO2012073256A128 Nov 20117 Jun 2012Cadila Healthcare LimitedSalts of rosuvastatin
WO2013080219A226 Nov 20126 Jun 2013Mylan Laboratories LtdNOVEL PROCESS FOR THE PREPARATION OF INTERMEDIATES OF HMG-CoA REDUCTASE INHIBITORS
WO2014108795A26 Jan 201417 Jul 2014Aurobindo Pharma LimitedAn improved process for the preparation of chiral diol sulfones and statins
WO2014142521A111 Mar 201418 Sep 2014Lg Life Sciences Ltd.Complex preparation including valsartan and rosuvastatin calcium and manufacturing method therefor
WO2014170786A13 Apr 201423 Oct 2014Pfizer Inc.N-piperidin-3-ylbenzamide derivatives for treating cardiovascular diseases
WO2015001573A14 Jul 20148 Jan 2015Cadila Healthcare LimitedSynergistic compositions
WO2015008294A118 Nov 201322 Jan 2015Suven Life Sciences LimitedProcess for the preparation of rosuvastatin calcium and preparation of its novel intermediates
WO2016055901A128 Sep 201514 Apr 2016Pfizer Inc.Substituted amide compounds
Classifications
U.S. Classification514/316, 544/322, 544/318
International ClassificationA61P3/06, C07D239/38, C07D239/34, C07D239/42, A61P43/00, A61K31/505, A61P9/10
Cooperative ClassificationC07D239/42, C07D239/38, C07D239/34
European ClassificationC07D239/38, C07D239/42, C07D239/34
Legal Events
DateCodeEventDescription
10 Oct 2003PTEFApplication for a patent term extension
Free format text: PRODUCT NAME: CRESTOR (ROSUVASTATIN CALCIUM); REQUESTED FOR 1304 DAYS
Filing date: 20031010
Expiry date: 20120612
24 Nov 2004FPAYFee payment
Year of fee payment: 12
30 May 2007PTEGGrant of a patent term extension
Free format text: PRODUCT NAME: CRESTOR (ROSUVASTATIN CALCIUM)
Filing date: 20031010
Expiry date: 20120612
14 May 2008356Patent term extension under 35 u.s.c. 156
Free format text: PRODUCT NAME: CRESTOR
Expiry date: 20120612
Extension date: 20160108